CAI
Caris Life Sciences, Inc.27.60
+0.90+3.37%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Guidance details, sales expansion unpacked
Q&A unpacked 2026 guidance granularity, splitting 20% volume growth into low-teens tissue and high-50s/low-60s blood, with Q1 revenues eyeing 70-74% growth yet no uplift from planned 20-25% sales force expansion to 300 reps baked in—benefits eyed for H2. Management defended conservative ASPs at $4,200 tissue and $2,400-$2,500 blood, signaling contract headroom. MCED specifics clarified high specificity in screening cohorts and $3,500 pricing justified by superior early-stage detection, though rarer cancers show small samples; full ACHIEVE-1 readout gates Q2 launch. CapEx phases $60M evenly for Nova X capacity. Answers largely reaffirmed scripted strength. Watch rep productivity, validation data.
Key Stats
Market Cap
7.79BP/E (TTM)
-Basic EPS (TTM)
-3.52Dividend Yield
0%Recent Filings
10-K
FY2025 results
Caris Life Sciences narrowed its FY2025 net loss to $68.1M from $281.9M in FY2024, driven by revenue doubling to $812M on 199,300 clinical cases—up from 162,850—with MI Profile cases accelerating to 170,300 (from 146,600) and Caris Assure surging to 29,000 (from 16,250) on higher reimbursement post-MI Cancer Seek FDA approval and broad launches. Q4 momentum shone through sequential case growth and ASP uplift from Medicare coverage under NGS NCD, yielding 67% gross margins (up from 43%) while operating income flipped positive at $45M. Cash flow turned robust at $83M from operations; $400M term debt at 10.5% weighs, but $800M liquidity buffers runway. DOJ probes Medicare billing rules persist as reimbursement risk.
8-K
Crushed 2025, eyes $1B+
8-K
Q4 revenue up 116% to $281M
Caris Life Sciences reported preliminary Q4 2025 revenue of $281M, up 116% year-over-year, fueled by $270M in molecular profiling including $81M true-ups; full-year revenue hit $800M, surging 94% with 199,300 cases completed, up 22%. Cash position strengthened to $802M. Results are unaudited and subject to change.
8-K
Q3 revenue soars 113%
Caris Life Sciences crushed Q3 2025 with $216.8M revenue, up 113% year-over-year, fueled by 121% molecular profiling growth to $207.6M and 68% gross margins. Net income hit $24.3M; cash flow turned positive at $62.4M operating. Revenue guidance jumped to $720-730M for 2025. Profitability flipped fast.
10-Q
Q3 FY2025 results
Caris Life Sciences swung to Q3 operating income of $32.6M from a $60.8M loss y/y, with revenue doubling 113% y/y to $216.8M (molecular profiling up 121% y/y to $207.6M) on 18% case growth and higher ASPs from MI Cancer Seek rollout. Gross margins expanded sharply to 68% from 44% y/y as volumes scaled. Cash swelled to $755M post-IPO, funding $38M operating cash flow (FCF $27M derived) against $376M long-term debt (10.8% rate, due 2028). Yet DOJ probes Medicare date-of-service compliance.
IPO
Employees
Sector
Industry
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CAHO
Caro Holdings Inc.
0.55+0.00
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CDIO
Cardio Diagnostics Holdings Inc
3.10+0.02
CDXS
Codexis, Inc.
1.68+0.05
CRBU
Caribou Biosciences, Inc.
1.69-0.02
HWAIF
HealWELL AI Inc.
0.64+0.00
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRVI
Maravai LifeSciences Holdings,
3.59-0.08